Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-catechin | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of OSGIN2 mRNA | CTD | PMID:24763279 | 1,2-dimethylhydrazine | decreases expression | ISO | Osgin2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of OSGIN2 mRNA | CTD | PMID:22206623 | 2-butoxyethanol | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | n-butoxyethanol results in increased expression of OSGIN2 mRNA | CTD | PMID:19812364 | 2-hydroxypropanoic acid | affects expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Lactic Acid affects the expression of OSGIN2 mRNA | CTD | PMID:30851411 | 4-hydroxyphenyl retinamide | decreases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of OSGIN2 mRNA | CTD | PMID:28973697 | acrolein | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSGIN2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of OSGIN2 mRNA | CTD | PMID:32699268 | acrylamide | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Acrylamide results in increased expression of OSGIN2 mRNA | CTD | PMID:32763439 | aflatoxin B1 | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of OSGIN2 mRNA | CTD | PMID:19770486 | aflatoxin B1 | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of OSGIN2 mRNA | CTD | PMID:27153756 | aflatoxin B1 | decreases methylation | ISO | OSGIN2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of OSGIN2 gene | CTD | PMID:27153756 | alpha-pinene | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSGIN2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of OSGIN2 mRNA | CTD | PMID:32699268 | aristolochic acid A | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of OSGIN2 mRNA | CTD | PMID:33212167 | benzo[a]pyrene | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of OSGIN2 mRNA | CTD | PMID:26238291 | benzo[a]pyrene | increases methylation | ISO | OSGIN2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of OSGIN2 5' UTR | CTD | PMID:27901495 | Benzo[k]fluoranthene | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | benzo(k)fluoranthene results in increased expression of OSGIN2 mRNA | CTD | PMID:26377693 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of OSGIN2 mRNA | CTD | PMID:30816183 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with tributyltin] results in decreased expression of OSGIN2 mRNA | CTD | PMID:31129395 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of OSGIN2 mRNA | CTD | PMID:31129395 | butanal | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of OSGIN2 mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of OSGIN2 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of OSGIN2 mRNA | CTD | PMID:35301059 | carbon nanotube | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of OSGIN2 mRNA | CTD | PMID:25620056 | chlorpyrifos | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of OSGIN2 mRNA | CTD | PMID:37019170 | choline | multiple interactions | ISO | Osgin2 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OSGIN2 gene | CTD | PMID:20938992 | cisplatin | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of OSGIN2 mRNA | CTD | PMID:27392435 | Cuprizon | affects expression | EXP | | 6480464 | Cuprizone affects the expression of OSGIN2 mRNA | CTD | PMID:27523638 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of OSGIN2 mRNA | CTD | PMID:26577399 | cyclosporin A | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of OSGIN2 mRNA | CTD | PMID:20106945 and PMID:25562108 | cyclosporin A | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of OSGIN2 mRNA | CTD | PMID:27989131 | dicrotophos | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of OSGIN2 mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSGIN2 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of OSGIN2 mRNA | CTD | PMID:29803840 | folic acid | multiple interactions | ISO | Osgin2 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OSGIN2 gene | CTD | PMID:20938992 | furan | increases expression | EXP | | 6480464 | furan results in increased expression of OSGIN2 mRNA | CTD | PMID:25539665 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of OSGIN2 mRNA | CTD | PMID:33387578 | hydrogen peroxide | affects expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of OSGIN2 mRNA | CTD | PMID:20044591 | L-methionine | multiple interactions | ISO | Osgin2 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of OSGIN2 gene | CTD | PMID:20938992 | leflunomide | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | leflunomide results in increased expression of OSGIN2 mRNA | CTD | PMID:28988120 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of OSGIN2 mRNA | CTD | PMID:25729387 | ozone | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of OSGIN2 mRNA more ... | CTD | PMID:32699268 | paracetamol | affects expression | ISO | Osgin2 (Mus musculus) | 6480464 | Acetaminophen affects the expression of OSGIN2 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of OSGIN2 mRNA | CTD | PMID:33387578 | pirinixic acid | multiple interactions | ISO | Osgin2 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of OSGIN2 mRNA | CTD | PMID:19710929 | pirinixic acid | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of OSGIN2 mRNA | CTD | PMID:23811191 | quercetin | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Quercetin results in increased expression of OSGIN2 mRNA | CTD | PMID:21632981 | rac-lactic acid | affects expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Lactic Acid affects the expression of OSGIN2 mRNA | CTD | PMID:30851411 | SB 431542 | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSGIN2 mRNA | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Silicon Dioxide results in increased expression of OSGIN2 mRNA | CTD | PMID:19073995 and PMID:33720480 | Soman | increases expression | EXP | | 6480464 | Soman results in increased expression of OSGIN2 mRNA | CTD | PMID:19281266 | succimer | multiple interactions | ISO | Osgin2 (Mus musculus) | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of OSGIN2 mRNA | CTD | PMID:21641980 | sulforaphane | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | sulforaphane results in increased expression of OSGIN2 mRNA | CTD | PMID:31838189 | sunitinib | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Sunitinib results in increased expression of OSGIN2 mRNA | CTD | PMID:31533062 | tetrachloromethane | increases expression | ISO | Osgin2 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of OSGIN2 mRNA | CTD | PMID:31919559 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of OSGIN2 mRNA | CTD | PMID:23411599 and PMID:34492290 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of OSGIN2 mRNA | CTD | PMID:25729387 | tributylstannane | decreases expression | EXP | | 6480464 | tributyltin results in decreased expression of OSGIN2 mRNA | CTD | PMID:31129395 | tributylstannane | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with tributyltin] results in decreased expression of OSGIN2 mRNA | CTD | PMID:31129395 | triptonide | affects expression | ISO | Osgin2 (Mus musculus) | 6480464 | triptonide affects the expression of OSGIN2 mRNA | CTD | PMID:33045310 | urethane | increases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Urethane results in increased expression of OSGIN2 mRNA | CTD | PMID:28818685 | valproic acid | affects expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of OSGIN2 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | OSGIN2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSGIN2 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | OSGIN2 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of OSGIN2 mRNA | CTD | PMID:26272509 and PMID:28001369 | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of OSGIN2 mRNA | CTD | PMID:23034163 | |